Drug Profile
AEG 33783
Alternative Names: AEG33783Latest Information Update: 15 Mar 2007
Price :
$50
*
At a glance
- Originator Aegera Therapeutics
- Class Antineoplastics; Neuroprotectants
- Mechanism of Action HSP70 heat shock protein stimulants; JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Diabetic neuropathies; Peripheral nervous system diseases
Most Recent Events
- 15 Mar 2007 Discontinued - Phase-I for Peripheral nervous system diseases in Canada (IV)
- 15 Mar 2007 Discontinued - Preclinical for Cancer in Canada (IV)
- 15 Mar 2007 Discontinued - Preclinical for Diabetic neuropathies in Canada (IV)